Tubular dysfunction is an important feature of renal injury in hepatorenal syndrome (HRS) in patients with end-stage liver disease. The pathogenesis of kidney injury in HRS is elusive, and there are no clinically relevant rodent models of HRS. We investigated the renal consequences of bile duct ligation (BDL)-induced hepatic and renal injury in mice in vivo by using biochemical assays, real-time polymerase chain reaction (PCR), Western blot, mass spectrometry, histology, and electron microscopy. BDL resulted in time-dependent hepatic injury and hyperammonemia which were paralleled by tubular dilation and tubulointerstitial nephritis with marked upregulation of lipocalin-2, kidney injury molecule 1 (KIM-1) and osteopontin. Renal injury was associated with dramatically impaired microvascular flow and decreased endothelial nitric oxide synthase (eNOS) activity. Gene expression analyses signified proximal tubular epithelial injury, tissue hypoxia, inflammation, and activation of the fibrotic gene program. Marked changes in renal arginine metabolism (upregulation of arginase-2 and downregulation of argininosuccinate synthase 1), resulted in decreased circulating arginine levels. Arginase-2 knockout mice were partially protected from BDL-induced renal injury and had less impairment in microvascular function. In human-cultured proximal tubular epithelial cells hyperammonemia per se induced upregulation of arginase-2 and markers of tubular cell injury. CONCLUSION: We propose that hyperammonemia may contribute to impaired renal arginine metabolism, leading to decreased eNOS activity, impaired microcirculation, tubular cell death, tubulointerstitial nephritis and fibrosis. Genetic deletion of arginase-2 partially restores microcirculation and thereby alleviates tubular injury. We also demonstrate that BDL in mice is an excellent, clinically relevant model to study the renal consequences of HRS. (Hepatology 2018; 00:000-000).
Tubular dysfunction is an important feature of renal injury in hepatorenal syndrome (HRS) in patients with end-stage liver disease. The pathogenesis of kidney injury in HRS is elusive, and there are no clinically relevant rodent models of HRS. We investigated the renal consequences of bile duct ligation (BDL)-induced hepatic and renal injury in mice in vivo by using biochemical assays, real-time polymerase chain reaction (PCR), Western blot, mass spectrometry, histology, and electron microscopy. BDL resulted in time-dependent hepatic injury and hyperammonemia which were paralleled by tubular dilation and tubulointerstitial nephritis with marked upregulation of lipocalin-2, kidney injury molecule 1 (KIM-1) and osteopontin. Renal injury was associated with dramatically impaired microvascular flow and decreased endothelial nitric oxide synthase (eNOS) activity. Gene expression analyses signified proximal tubular epithelial injury, tissue hypoxia, inflammation, and activation of the fibrotic gene program. Marked changes in renal arginine metabolism (upregulation of arginase-2 and downregulation of argininosuccinate synthase 1), resulted in decreased circulating arginine levels. Arginase-2 knockout mice were partially protected from BDL-induced renal injury and had less impairment in microvascular function. In human-cultured proximal tubular epithelial cells hyperammonemia per se induced upregulation of arginase-2 and markers of tubular cell injury. CONCLUSION: We propose that hyperammonemia may contribute to impaired renal arginine metabolism, leading to decreased eNOS activity, impaired microcirculation, tubular cell death, tubulointerstitial nephritis and fibrosis. Genetic deletion of arginase-2 partially restores microcirculation and thereby alleviates tubular injury. We also demonstrate that BDL in mice is an excellent, clinically relevant model to study the renal consequences of HRS. (Hepatology 2018; 00:000-000).
Authors: John W Bullen; Irina Tchernyshyov; Ronald J Holewinski; Lauren DeVine; Fan Wu; Vidya Venkatraman; David L Kass; Robert N Cole; Jennifer Van Eyk; Gregg L Semenza Journal: Sci Signal Date: 2016-05-31 Impact factor: 8.192
Authors: Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh Journal: Hepatology Date: 2012-12-06 Impact factor: 17.425
Authors: Debbie L Shawcross; Gavin A K Wright; Vanessa Stadlbauer; Stephen J Hodges; Nathan A Davies; Caroline Wheeler-Jones; Andrew A Pitsillides; Rajiv Jalan Journal: Hepatology Date: 2008-10 Impact factor: 17.425
Authors: Laurel L Ballantyne; Yuan Yan Sin; Osama Y Al-Dirbashi; Xinzhi Li; David J Hurlbut; Colin D Funk Journal: Mol Genet Metab Rep Date: 2016-10-12
Authors: Roosmarijn E Vandenbroucke; Christophe Van Steenkiste; Wouter Claeys; Lien Van Hoecke; Anja Geerts; Hans Van Vlierberghe; Sander Lefere; Griet Van Imschoot; Elien Van Wonterghem; Bart Ghesquière Journal: Sci Rep Date: 2022-10-20 Impact factor: 4.996
Authors: Csaba Matyas; Katalin Erdelyi; Eszter Trojnar; Suxian Zhao; Zoltan V Varga; Janos Paloczi; Partha Mukhopadhyay; Balazs T Nemeth; György Haskó; Resat Cinar; Robim M Rodrigues; Yeni Ait Ahmed; Bin Gao; Pal Pacher Journal: Hepatology Date: 2020-01-24 Impact factor: 17.298
Authors: Eva Nora Bukosza; Tamás Kaucsár; Mária Godó; Enikő Lajtár; Pál Tod; Gábor Koncsos; Zoltán V Varga; Tamás Baranyai; Minh Tu Nguyen; Helga Schachner; Csaba Sőti; Péter Ferdinandy; Zoltán Giricz; Gábor Szénási; Péter Hamar Journal: Int J Mol Sci Date: 2019-08-30 Impact factor: 5.923
Authors: Anna C Croce; Giovanni Bottiroli; Laura G Di Pasqua; Clarissa Berardo; Veronica Siciliano; Vittoria Rizzo; Mariapia Vairetti; Andrea Ferrigno Journal: Int J Mol Sci Date: 2018-09-05 Impact factor: 5.923